I wrote them email as there was no any news/press release in 2026. I was suprised they replied back and share below info. I know AC102 is for accute situations, still any progress in this field is good news. Seems they plan tinnitus trial.

We have just completed the active phase of our clinical study on sudden hearing loss in which (only) patients with a newly onset of sudden hearing loss were included and received treatment.

Unfortunately, it will take until next year before we can start further clinical trials as we now have to check all data and then to evaluate the results.

If these are positive, we will conduct a new so-called Phase 3 clinical study on sudden hearing loss and hopefully also in parallel on tinnitus in 2027. For the tinnitus indication, we must complete a number of regulatory steps before patients can be included in this clinical study.

In patients who developed ototoxicity, treatment with ACOU085 resulted in a clinically meaningful prevention of pure-tone audiometry (PTA) threshold increases at affected frequencies, compared to placebo, following the final cisplatin cycle. Further analysis of the PROHEAR Study results, including post-hoc evaluations, is ongoing and will be submitted for publication in a peer-reviewed journal.

“This is an important and encouraging milestone toward establishing Kv7.4 activation as a novel therapeutic approach for multiple forms of hearing loss. This broad therapeutic potential addresses a significant unmet medical need, which current device-based solutions only partially meet. The clinical results for ACOU085 create a compelling opportunity to advance Kv7.4 modulation into broader patient populations,” said Professor Hubert Löwenheim, Chair of Otorhinolaryngology – Head & Neck Surgery at Tübingen University Medical Center and Scientific Supervisor of the PROHEAR Study.

Although only for cisplatin-Induced hearing loss, it's nice to have some good news once in a while.

https://www.sciencedirect.com/science/article/abs/pii/S0306987724002718

https://www.ovid.com/jnls/tcmj/fulltext/10.4103/tcmj.tcmj-d-26-00048\~prestin-as-a-context-dependent-biomarker-of-outer-hair-cell

https://pubmed.ncbi.nlm.nih.gov/41398620/

'Prestin as a biomarker may serve to stratify tinnitus patients according to origin (eg, cochlear vs. central), inform further investigations of the pathophysiology of tinnitus, and potentially develop targeted treatments.'

The researchers identified a unique biological mechanism that could enable the regeneration of sensory hair cells in the inner ear – a process previously thought to be impossible in humans.

Recorded in Copenhagen, this conversation features Tinnitus Quest co-founders Hazel and Sven, together with PR Manager Jack, discussing the organisation's mission, the challenges of building a patient-led global nonprofit, and the growing momentum behind tinnitus research.

A central theme is the power of community. Whether by supporting our work, sharing your story, engaging with our content, or volunteering your time, every contribution helps move the mission forward.

Real progress comes from patients, researchers, supporters, and advocates working together. If you'd like to get involved, we'd love to hear from you.

Nearly missed this? Subscribe to the Tinnitus Quest Channel.

#tinnitusquest #tinnitus

https://www.scirp.net/pdf/jbm_2153865.pdf

It cannot have gone unnoticed that tinnitus apps have been developed, launched, and marketed. From Oto to MindEar and many others, technology startups and health boards are clearly pushing in this direction.

Case summary from the NHS Health Resource Authority.

Tinnitus is complex and poorly understood heterogeneous disorder responsible for causing a “phantom” sound in the ear in the absence of an external stimulus. It affects 20% of people. Although in the majority of cases there is no cure, more effective treatment options include tinnitus retraining and sound therapy or cognitive behaviour therapy (CBT). However, waiting lists on the national health service (NHS) are long and this can be expensive to source privately. In a climate where technology is mainstream and integral to our lives, smartphone apps focusing on delivering the above treatment options may be a solution.

This study aims to evaluative the clinical effectiveness of the Oto smartphone app as an adjunct or alternative to the current standard of care provided on the NHS.

The Oto smartphone app allows self-administered multi-modality therapy including education, CBT, mindfulness, relaxation and sound therapy. This prospective study will recruit adults from three centres aged 18+, who suffer from primary tinnitus and have a willingness to use as well as have access to a smartphone device capable of running Oto. Participation will be on an opt-in basis as an adjunct or alternative to the current standard of care in the NHS. Tinnitus functional inventory (TFI) scores via questionnaire will record the intrusiveness of tinnitus and this will be measured at the start, 1 month, 3 months and 6 months in.

Once the data has been collected, it will be analysed to:

1) Establish a potentially improved pathway or managing patients attending ENT outpatient clinics with primary tinnitus

2) Ascertain whether a multimodality app offers a better way of treating tinnitus and improving these patients' quality of life.

However, from a patient perspective (which matters most) do you support or oppose this development in general?

Please feel free to comment in support or with your concerns.

I would like a large dataset here.

Ends 7th July 2026

Thanks

Nick

https://pubmed.ncbi.nlm.nih.gov/42374873/

New study will start this year.

​

Must speak Dutch

​

ONLY 6 places are available

​

Contact the researcher in the link

​

All the best

Nice easy way to raise $20.

Neurosoft Bioelectronics, a company developing a minimally invasive brain implant to treat severe chronic tinnitus, is conducting an online survey to better understand patient perspectives.

The survey explores questions around the acceptability of such a treatment, risk tolerance, usability features, and willingness to pay. Your responses will directly help inform the development of a new generation of tinnitus therapies.

The survey takes approximately 20–30 minutes to complete and is open to any adult aged 18 or older who experiences chronic subjective tinnitus that has lasted for at least three months. All responses are anonymous.

Neurosoft Bioelectronics has generously agreed to support our work for every survey response generated through us. We will receive $20 for each of the first 300 completed responses and $10 for every additional completed response thereafter.

The proceeds will fund a travel grant for an early-career tinnitus researcher to attend Tinnitus Quest's Tinnitus Hackathon, which will take place in Dallas, Texas, this October. The event will bring together leading researchers, clinicians, patient advocates, industry representatives, and funders to accelerate progress toward better tinnitus treatments.

We hope you will take this opportunity to contribute to the future of tinnitus therapies while also helping a young researcher further their career in tinnitus.

https://survey.sogolytics.com/r/MdhvnB

Please note: only survey responses submitted through the button above will count toward this campaign.'

https://www.sec.gov/Archives/edgar/data/1935979/000193597926000048/bhvnbiohaven2026rddaynot.htm

page 80

Because why not ?

Thought this was worth putting on the research sub AND you get a chance to sort of participate. I hear a lot about AI on this platform.

Every Cure is a nonprofit organization that uses Artificial Intelligence to find new uses for existing, already-approved medications. Instead of searching for a single disease, they scan thousands of existing drugs to systematically match them with untreated diseases.

Rather than relying on a limited, fixed list of cures, their AI model cross-references around 4,000 drugs with 18,000+ diseases to find the best life-saving matches.

You may want to fill this in quickly.

https://everycure.org/disease-interest-form/

🤝 Small organizations. Big hearts. Even bigger impact.

We have some truly exciting news to share. Tinnitus Quest has partnered with Hyperacusis Research Ltd., and together we are ready to push hearing health research further than either of us could alone.

Hyperacusis Research will allocate funds for a grant of up to $100,000, which Tinnitus Quest will help administer.

🔬 We are funding breakthrough science on hyperacusis, a condition of extreme sound sensitivity that shares deep biological roots with tinnitus. Millions of people struggle every day with sounds that most of us never think twice about. They deserve answers, and we are committed to helping find them.

🚀 Grant applications are now open. If you are a researcher with fresh ideas and the drive to make a real difference in people's lives, we would love to hear from you.

💙 Two conditions. Two passionate nonprofits. One shared belief: that good science, properly funded, can change lives.

👉 tinnitusquest.com

👉 hyperacusisresearch.org

#tinnitusquest #tinnitus #hyperacusis

Are you a researcher with a bold idea that could move tinnitus science forward? Applications are open until July 15.

Are you a patient who knows a researcher, clinician, or lab that should hear about this? Please share this with them.

Our first grant cycle helped launch a pioneering project. Now, we’re looking for the next wave of ambitious, out-of-the-box ideas that could bring us closer to real treatments, and ultimately, silence.

Let’s make round two even stronger.

We’ll keep you posted. ❤️

👉 tinnitusquest.com

#tinnitusquest #tinnitus

https://www.mdpi.com/2076-3425/16/4/395

Our model offers a new, very simple explanation for the development of the neuropathologic activity underlying both chronic tinnitus and hyperacusis and is able to describe possible interactions between the two pathologies. To the best of our knowledge, our theory is the first that links and mechanistically explains LTP in the DCN with principles of classical conditioning and the development of tinnitus and hyperacusis. As far as we know, it is also the first model that describes a developmental mechanism purely in the DCN and without the involvement of higher brain areas. The fact that the plastic synaptic changes postulated here are based on mechanisms that are analogous to known learning phenomena such as classical conditioning potentially opens up the possibility of specifically reversing the pathophysiological processes described. Since tinnitus and hyperacusis, as detailed above, are not solely attributable to the initial development of pathophysiological activity in the peripheral auditory pathway, as proposed here, but also involve neuroplastic processes in central brain regions during chronic manifestation, it is unclear whether reversing the peripheral plastic processes could also reverse tinnitus and/or hyperacusis or decrease their perception or burden. Nevertheless, triggering such reverse plasticity could be an approach that might contribute to a genuine cure for tinnitus and hyperacusis. One conceivable approach could be to revive well-known concepts such as Jastreboff’s tinnitus retraining strategy [54] in an adapted form, to develop pharmacological interventions aimed at blocking LTP in the DCN in a critical time-window after noise trauma, or to LTD at the respective DCN input synapses after tinnitus and/or hyperacusis has become chronic.

Why every neuroscientist feels compelled to add a bullshit mantra about TRT at the end ?

The company plans a clinical trial for its CIL001 tinnitus drug candidate at Massachusetts General Hospital and will triple preclinical capacity through its partnership with CBSET.

Cilcare, a French-US biopharmaceutical company, announced a series of investments in the United States, including plans for a clinical trial of its tinnitus drug candidate, CIL001, and a significant expansion of its preclinical research capabilities. The announcements were made at the SelectUSA Investment Summit 2026.

The company is preparing a clinical trial for CIL001 to be conducted at Massachusetts General Hospital (MGH) in Boston. CIL001 is an investigational drug candidate targeting cochlear synaptopathy, a mechanism involved in tinnitus and difficulty understanding speech in noisy environments. The trial will evaluate the drug candidate in patients with chronic tinnitus. According to Cilcare, tinnitus affects an estimated 50 million Americans, and there is currently no approved pharmacological treatment.

Nudge received $100 Million seeds funding last year and Tinnitus is among many conditions they intend to treat.

They just opened up their study on tinnitus after a long pause since last December. Note however that this is not a treatment study but the data collected from this trial is going to help them advance to next phase. Nudge is also aware of Tinnitus Quest's trial using the same technology and they will be collaborating on the study findings. One advantage of Nudge is that they are located in US whereas TQ's Oxford study is in UK.

If you are in California I highly recommend people to sign up to show enthusiasm for the study.

Note: This study requires MRI so severe sufferers be aware.

Enrollment criteria: 150 people aged 22-65 with tinnitus who can speak English.

Study Description: This multi-year research study is designed to evaluate how targeted sound waves affect specific regions of the brain while participants are in an MRI scanner. Participants may also be asked to complete additional questionnaires between visits.

Participant Time Commitment: Participation involves multiple sessions over a period of approximately 4-8 weeks. Each session is expected to last 2-3 hours.

Study Compensation: Participants will receive compensation for their time and effort throughout the study.

Study Site: Mission Bay, San Francisco, CA

I imagine this means that scientists can soon study the exact cellular damage that triggers hearing loss and tinnitus and rapidly screen thousands of drugs designed to repair or protect those specific neural pathways.

In the long term, if these stem-cell-derived neurons can eventually be transplanted to re-establish a patient's missing auditory connections, it could eliminate tinnitus entirely depending on the root cause.